

1 December 2014

Announcements
National Stock Exchange of Australia
PO Box 283
NEWCASTLE NSW 2300

Market Announcement - Retirement of Director

In accordance with rule 6.17 (2) of Section IIA of the NSX Listing and Business Rules, iQnovate Limited (NSX:IQN) today announce the following change to its Board, with effect from 25 November 2014.

Mr William Economos, Non-Executive Director, has retired from his position as a member of the Board of iQnovate Limited. In accordance with the Company's Constitution, Mr Economos retired by rotation at the iQnovate Limited Annual General Meeting held on 25 November 2014. Mr Economos did not seek re-election to the Board and therefore is no longer a Director holding office as from the close of the Annual General Meeting.

Mr Economos has been a valuable member of the Board for in excess of 3 years. On behalf of the Company, the Chairman, Dr George Symmalis, extended his gratitude to Mr Economos for his valued contribution to the Company during that time, and wished him well in retirement.



Kelvin Boateng
Company Secretary

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with iQnovate's business can be found in its periodic filings with the National Stock Exchange of Australia.

SOURCE iQnovate Limited

iQnovate Ltd is a life science organisation, providing intellectual property asset management services and scientific advice to the global Biopharmaceutical industry.

Whether the asset is a pharmaceutical, medical device, technology platform or a compound in development, iQnovate will effectively manage your asset through its complete life cycle, from clinical trials right through to maturity.

iQnovate clients are pharmaceutical, biotechnology, medical device companies as well as financial institutions, academic and government organisations.